INNOVACIONES TERAPÉUTICAS EN EL MANEJO DE LA DIABETES TIPO 2: ENFOQUE EN LOS MODULADORES DEL RECEPTOR GLP-1
Keywords:
Oral hygiene, orthodontics, brushing techniques, mouth rinses, plaque control.Abstract
Type 2 diabetes mellitus remains a major global public health challenge. In recent years, the development of glucagon-like peptide-1 receptor (GLP-1) agonists has transformed the therapeutic approach to this chronic disease. These agents not only improve glycemic control but also provide additional benefits, such as weight reduction and cardiovascular risk mitigation. This review offers an update on the latest advancements in the treatment using GLP-1 receptor modulators, emphasizing their efficacy, safety, and clinical applications. Furthermore, it explores their mechanisms of action, potential adverse effects, and their inclusion in current clinical guidelines. The analysis highlights the promising role of GLP-1 therapies in the evidence-based and individualized management of type 2 diabetes.
Downloads
References
Villalba Leonardo M. Diabetes mellitus: los orígenes de un no tan dulce término. Medicas UIS. 2022 [citado 23/08/2025];35(3):75-81. Disponible en: http://www.scielo.org.co/pdf/muis/v35n3/1794-5240-muis-35-03-75.pdf
Zhikai Z , Yao Z , Yiyang M , Yucheng T , Yidan P , Changqing Z, Junjie G. Receptor del péptido similar al glucagón-1: mecanismos y avances en la terapia. Transducción de señales y terapia dirigida. 2024 [citado 23/08/2025];9(234):1-29. Disponible en: https://www.nature.com/articles/s41392-024-01931-z.pdf
Salvadora J, Gaztambideb S.Los agonistas del receptor del GLP-1: un abordaje terapéutico eficaz de amplio espectro en el tratamiento de la diabetes mellitus tipo 2. Med Clin (Barc). 2014 [citado 23/08/2025];143(Suppl2):1-7. Disponible en: https://www.elsevier.es/es-revista-medicina-clinica-2-articulo-los-agonistas-del-receptor-del-S0025775314701009
Mejía-Zambrano H. Efectos de los agonistas del receptor de péptido similar al glucagón tipo 1 como tratamiento en pacientes con obesidad y diabetes mellitus tipo 2. Rev haban cienc méd. 2022 [citado 23/08/2025];21(3). Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1729519X2022000300003&lng=es.
Sijin W , Wenzhao L , Zhongli C , Yan D , Keping C , Shu Z. Association of glucagon-like peptide-1 receptor agonists with cardiac arrhythmias in patients with type 2 diabetes or obesity: a systematic review and meta-analysis of randomized controlled trials. Diabetol Metab Syndr. 2022 [citado 23/08/2025];14(1):195. Disponible en: https://pmc.ncbi.nlm.nih.gov/articles/PMC9791739/pdf/13098_2022_Article_970.pdf
Xiaomei C, Xuge Z, Xiang X, Xiang F,Shenghong F. Effects of glucagon-like peptide-1 receptor agonists on cardiovascular outcomes in high-risk type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Diabetology & Metabolic Syndrome volume. 2024 [citado 23/08/2025];16(251):1-13. Disponible en: https://dmsjournal.biomedcentral.com/articles/10.1186/s13098-024-01497-4
Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomized placebo-controlled trial. Lancet. 2019 [citado 23/08/2025];394(10193):121-30. Disponible en: https://www.sciencedirect.com/science/article/abs/pii/S0140673619311493
Mann JFE, Orsted DD, Brown-Frandsen K, Marso SP, Poulter NR, Rasmussen S, et al. Liraglutide and renal outcomes in type 2 diabetes. N Engl J Med. 2017 [citado 23/08/2025];377(9):839-48. Disponible en: https://www.nejm.org/doi/full/10.1056/NEJMoa1616011
Meier JJ, Wefers J, Quast DR, Nauck MA GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art. Mol Metab. 2020 [citado 23/08/2025];46:101102.Disponible en: https://pmc.ncbi.nlm.nih.gov/articles/PMC8085572/pdf/main.pdf
Collins L; Costello RA. Glucagon-like peptide-1 receptor agonists. StatPearls. 2024 [citado 23/08/2025]. Disponible en: https://www.ncbi.nlm.nih.gov/books/NBK551568/?report=reader
Drucker DJ. The biology of incretin hormones. Cell Metab. 2006 [citado 23/08/2025];3(3):153-65. Disponible en: https://linkinghub.elsevier.com/retrieve/pii/S1550-4131(06)00028-3
Caruso I, Cignarelli A, Pio Sorice G , Natalicchio A , Perrini S , Laviola L. Cardiovascular and Renal Effectiveness of GLP-1 Receptor Agonists vs. Other Glucose-Lowering Drugs in Type 2 Diabetes: A Systematic Review and Meta-Analysis of Real-World Studies. Metabolites. 2022 [citado 23/08/2025];12(2):183. Disponible en: https://pmc.ncbi.nlm.nih.gov/articles/PMC8879165/
Barkmeier AJ, Singh RP, Hodge DO. Uso de agonistas del receptor del péptido 1 similar al glucagón y riesgo de retinopatía diabética: un estudio de base de datos. (Congreso Anual de la American Society of Retina Specialists (ASRS)). 8-12 Agosto 2024; Suecia.
American Diabetes Association. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2022. Diabetes Care. 2022 [citado 23/08/2025];45(Suppl.1):S125-S143. Disponible en: https://diabetesjournals.org/care/article/45/Supplement_1/S125/138908/9-Pharmacologic-Approaches-to-Glycemic-Treatment
Shujin F, Qiu Y, Liu J, Zhu T, Wang C, Liu D, et.al. Efecto de los agonistas del receptor del péptido similar al glucagón-1 en la neuropatía periférica diabética: un metanálisis. JNC. 2024 [citado 23/08/2025];169(2):e16242.Disponible en: https://onlinelibrary-wiley-com.translate.goog/doi/full/10.1111/jnc.16242?_x_tr_sl=en&_x_tr_tl=es&_x_tr_hl=es&_x_tr_pto=tc
Kapoor I, Sarvepalli SM , D'Alessio D, Grewal DS, Hadziahmetovic M. Agonistas del receptor GLP-1 y retinopatía diabética: un metaanálisis de ensayos clínicos aleatorizados. Oftalmol de supervivencia. 2023 [citado 23/08/2025];68(6):1071-1083. Disponible en: https://pubmed-ncbi-nlm-nih-gov.translate.goog/37454782/
Abasheva D, Ortiz A, Fernandez-Fernandez B. GLP-1 receptor agonists in patients with chronic kidney disease and either overweight or obesity. Clin Kidney J. 2024 [citado 23/08/2025];17(Suppl2):ii19–ii35. Disponible en: https://pmc.ncbi.nlm.nih.gov/articles/PMC11581768/pdf/sfae296.pdf
Esparza-Olcina MJ, Fernández-Rodríguez MM. La metformina podría ser un apoyo en el tratamiento de la obesidad. Rev Pediatr Aten Primaria. 2021 [citado 20/08/2025];23(92):429-432. Disponible en: http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S113976322021000400020&lng=es
Rico-Fontalvo J, Daza-Arnedo R, Raad-Sarabia M, Pájaro-Galvis N, Correa-Guerrero J, Villacob-Oviedo A,et.al. Agonistas del receptor de GLP-1: desde su efecto fisiológico en el sistema incretina hasta su rol en enfermedad renal diabética. ARCHIVOS DE MEDICINA.2021 [citado 20/08/2025];17(22):1-12. Disponible en: https://www.archivosdemedicina.com/medicina-de-familia/agonistas-del-receptor-glp1-desde-su-efecto-fisiologico-en-el-sistema-incretina-hasta-du-rol-en-enfermedad-renal-diabetica.pdf
Verma S, McGuire DK, Bain SC, Mazer M, Fries M, Bhatt DL, et al. Effects of glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across body mass index categories in type 2 diabetes: Results of the LEADER and SUSTAIN 6 trials. Diabetes Obes Metab. 2020 [citado 20/08/2025];22(12):2487-2492. Disponible en: https://dom-pubs.onlinelibrary.wiley.com/doi/full/10.1111/dom.14160
Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Leiter LM, Jódar E,et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016 [citado 20/08/2025];375(19):1834-1844. Disponible en: https://www.nejm.org/doi/full/10.1056/NEJMoa1607141
American Diabetes Association. Enfoques farmacológicos para el tratamiento de la glucemia: Estándares de atención en diabetes—2025.Diabetes Care. 2025 [citado 20/08/2025];48(Suppl1):S181–S206. Disponible en: https://diabetesjournals-org.translate.goog/care/article-pdf/48/Supplement_1/S181/791515/dc25s009.pdf?_x_tr_sl=en&_x_tr_tl=es&_x_tr_hl=es&_x_tr_pto=tc
Guyton J , Jeon M , Brooks A. Glucagon-like peptide 1 receptor agonists in type 1 diabetes mellitus. Am J Health Syst Pharm. 2019 [citado 20/08/2025];76(21):1739-1748. Disponible en: https://academic.oup.com/ajhp/article-lookup/doi/10.1093/ajhp/zxz179
Teixeira L, Luizon MR, Gomes KB. Exploring the Role of GLP-1 Receptor Agonists in Alzheimer’s Disease: A Review of Preclinical and Clinical Evidence. MDPI. 2025 [citado 20/08/ 2025]; 4(1):2. Disponible en: https://www.mdpi.com/2813-2564/4/1/2
Davies Melanie J, Aroda V, Collins B, Gabbay R, Green J, Maruthur N,et.al. Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2022 [citado 20/08/2025];45(11):2753–2786. Disponible en: https://diabetesjournals.org/care/article/45/11/2753/147671/Management-of-Hyperglycemia-in-Type-2-Diabetes
Lupien-Meilleur J, Andrich DE, Quinn S, Micaelli-Baret C, St-Amand R, Roy D,et.al. Interplay Between Gut Microbiota and Gastrointestinal Peptides: Potential Outcomes on the Regulation of Glucose Control. Canadian Journal of Diabetes. 2020 [citado 20/08/2025];44(4):359-367. Disponible en: https://www.sciencedirect.com/science/article/abs/pii/S1499267119306811
Bielka W, Przezak A, Pawlik A. The Role of the Gut Microbiota in the Pathogenesis of Diabetes. Int J Mol Sci. 2022 [citado 20/08/2025];23(1):480. Disponible en: https://pmc.ncbi.nlm.nih.gov/articles/PMC8745411/pdf/ijms-23-00480.pdf
Escobara Almudena C, Gómez Cerezo JF, Górriz JL, Obaya Rebollard JC, Villar-Taibo R.Abordaje práctico de la semaglutida en el paciente con diabetes tipo 2. Rev Esp Cardiol. 2022 [citado 20/08/2025];22(SD):139-146. Disponible en: https://www.revespcardiol.org/es-abordaje-practico-semaglutida-el-paciente-articulo-S1131358722000139
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Olivia Elizabeth Altamirano Guerrero , Christian Alexis Avila Diaz , Kevin René Lara Quinatoa, Heydi Nicole Paguay Pingos
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
ACCESS AND DISTRIBUTION POLICY
All published articles are open access contributions, which are distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License which permits unrestricted non-commercial use, distribution and reproduction in any medium, provided that the primary source of publication is properly cited.
